Treating blood or blood product with a compound having a mustard and a nucleic acid binding moiety
AssigneeCerus Corporation
InventorsDavid Cook, Susan Wollowitz, Aileen Nerio
Life of this patent
Estimating the term…
Abstract
Methods and compositions for treating pathogens in material are described, including methods of decontaminating human fluids prior to processing in the clinical laboratory and methods for decontaminating blood products prior to in vivo use. The techniques handle large volumes of human serum without impairing the testing results. Novel compounds for photodecontaminating biological material are also contemplated which are compatible with clinical testing, in that they do not interfere with serum analytes.
Claims21
An in vitro method of treating mammalian blood or a blood product to inactivate a viral, bacterial or protozoan pathogen, the method comprising:
- (a) contacting in vitro a mammalian blood or blood product with a viral, bacterial or protozoan pathogen inactivating amount of a compound I, wherein,
- (i) compound I has an intercalator nucleic acid binding ligand and a mustard group attached thereto, and
- (ii) compound I when incubated with a composition comprising a blood product containing R17, has a greater inactivation efficiency against R17 than a compound II containing a mustard group that lacks the intercalator nucleic acid binding ligand, and
- (iii) the treating with the pathogen inactivating amount of Compound I results in the inactivation of at least 1 log of pathogen present in the blood or blood product, if any;
- and
- (b) recovering the pathogen inactivated mammalian blood or blood product, wherein the recovered product has substantially the same biological activity such that it is suitable for therapeutic use in a mammal.
Dependencies are inferred from the claim text.